

02. Drug development: something old, something new
Friday, 04 December 2015, 12:30-13:30

Chair: Agnes GEBHARD (Netherlands)

Track: Drug-sensitive TB care and treatment, including trials

- PC-708-04** **Laboratory and non-clinical evaluation of pulmonary drug delivery in TB**
S Pandya, A Gupta, R Ranjan, M Sachan, A Srivastava, A Misra (*India*)
- PC-709-04** **Can vitamin C augment sputum conversion in TB patients while on anti-tuberculosis treatment?**
L Gujral, S Mugudalabetta, R K Ramalingapuram Muthusloahy (*India*)
- PC-710-04** **Identification of optimal dose and dosing regimen of clofazimine for the treatment of MDR-TB based on pharmacokinetic modeling**
G Subramanian, G Sunkara, D Mcneeley, D Hughes (*India, USA, Switzerland*)
- PC-711-04** **A comparison of the effectiveness of a six- versus eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions**
K Ukwaja, S Oshi, I Alobu, D Oshi (*Nigeria*)
- PC-712-04** **Therapeutic drug monitoring of isoniazid and rifampicin**
L Moreno Exebio, L Lecca, G R Davies (*Peru, UK*)
- PC-713-04** **Plasma concentration of first-line anti-tuberculosis drugs in relation to minimal inhibitory concentrations: a prospective observational study**
K Niward, L Davies-Forsman, J Bruchfeld, J Paues, E Eliasson, J Werngren, U Simonsson, T Schön (*Sweden*)
- PC-714-04** **The role of wild-type distributions and epidemiological cut-offs in determining breakpoints for susceptibility testing against *M. tuberculosis***
T Schön (*Sweden*)
- PC-715-04** **Spectinamides: a new class of semisynthetic protein synthesis inhibitors against tuberculosis that overcome native drug efflux**
R.e Lee, B Meibohm, A Lenaerts, E.c. Boettger, M.m. Butler, T.I. Bowlin (*USA*)
- PC-716-04** **Comparing the efficacy of drug regimens for patients with drug-sensitive pulmonary tuberculosis – an aggregate data meta-analysis of phase II studies**
L Bonnett, G R Davies (*UK*)